blank Quick help
blank Maintenance news

Scheduled maintenance

Regular maintenance outages:
between 05.00 and 05.15 hrs CET (Monday to Sunday).

Other outages
Availability

2022.02.11

More...
blank News flashes

Italy joins the Federated Register

Click here for more information on the Federated Register.

2025-06-12

More...
blank Related links

Release notes
European Patent Register Assistant
European Patent Register User Manual
European Patent Register – pocket guide
FAQ - European Patent Register
Federated Register (Flyer)
Global Dossier (Flyer)
Register events
Deep link coverage
Federated Register content
The Patent Information Tour
Fair use charter

Extract from the Register of European Patents

EP About this file: EP3140398

EP3140398 - TAL-EFFECTOR NUCLEASE FOR TARGETED KNOCKOUT OF THE HIV CO-RECEPTOR CCR5 [Right-click to bookmark this link]
StatusOpposition rejected
Status updated on  02.04.2022
Database last updated on 07.04.2026
FormerThe patent has been granted
Status updated on  26.07.2019
FormerGrant of patent is intended
Status updated on  22.03.2019
FormerExamination is in progress
Status updated on  22.09.2017
FormerRequest for examination was made
Status updated on  10.02.2017
FormerThe international publication has been made
Status updated on  18.11.2016
Most recent event   Tooltip08.07.2022Lapse of the patent in a contracting state
New state(s): MK		published on 10.08.2022  [2022/32]
Applicant(s)For all designated states
ADVANCED GENE & CELL TECHNOLOGIES LLC (AGCT LLC)
194291 Lunacharskogo str. 35-51
Saint-Petersburg / RU
[2017/11]
Inventor(s)01 / MOCK, Ulrike
10 Stadium Mews
London N5 1FP / GB
02 / FEHSE, Boris
Hagenbeckstrasse 171A
22527 Hamburg / DE
 [2017/11]
Representative(s)Stüven, Ralf
RGTH Patentanwälte PartGmbB
Kirchenhang 32b
21073 Hamburg / DE
[N/P]
Former [2017/11]Stüven, Ralf, et al
Pohl & Partner
Patentanwälte
Kirchenhang 32 b
21073 Hamburg / DE
Application number, filing date15744474.604.05.2015
[2017/11]
WO2015DE200295
Priority number, dateDE20141010632707.05.2014         Original published format: DE102014106327
[2017/11]
Filing languageDE
Procedural languageDE
PublicationType: A1 Application with search report
No.:WO2015169314
Date:12.11.2015
Language:DE
[2015/45]
Type: A1 Application with search report 
No.:EP3140398
Date:15.03.2017
Language:DE
The application published by WIPO in one of the EPO official languages on 12.11.2015 takes the place of the publication of the European patent application.
[2017/11]
Type: B1 Patent specification 
No.:EP3140398
Date:28.08.2019
Language:DE
[2019/35]
Search report(s)International search report - published on:EP12.11.2015
ClassificationIPC:C12N9/22, C12N15/90
[2017/11]
CPC:
C12N9/22 (EP,IL,KR,US); A61K48/00 (KR); A61P31/18 (EP);
A61P43/00 (EP); C12N15/111 (EP,KR,US); C12N15/902 (IL,KR);
C07K2319/80 (EP,IL,KR,US); C12N2310/20 (EP,US) (-)
Designated contracting statesAL,   AT,   BE,   BG,   CH,   CY,   CZ,   DE,   DK,   EE,   ES,   FI,   FR,   GB,   GR,   HR,   HU,   IE,   IS,   IT,   LI,   LT,   LU,   LV,   MC,   MK,   MT,   NL,   NO,   PL,   PT,   RO,   RS,   SE,   SI,   SK,   SM,   TR [2017/11]
Extension statesBANot yet paid
MENot yet paid
Validation statesMANot yet paid
TitleGerman:TAL-EFFEKTORNUKLEASE ZUM GEZIELTEN KNOCKOUT DES HIV-KOREZEPTORS CCR5[2017/11]
English:TAL-EFFECTOR NUCLEASE FOR TARGETED KNOCKOUT OF THE HIV CO-RECEPTOR CCR5[2017/11]
French:NUCLÉASE EFFECTRICE TAL POUR LE KNOCK-OUT CIBLÉ DU CO-RÉCEPTEUR DU VIH CCR5[2017/11]
Entry into regional phase07.12.2016National basic fee paid 
07.12.2016Designation fee(s) paid 
07.12.2016Examination fee paid 
Examination procedure06.12.2016Date on which the examining division has become responsible
07.12.2016Examination requested  [2017/11]
20.06.2017Amendment by applicant (claims and/or description)
25.09.2017Despatch of a communication from the examining division (Time limit: M06)
29.03.2018Reply to a communication from the examining division
11.05.2018Despatch of a communication from the examining division (Time limit: M06)
19.11.2018Reply to a communication from the examining division
01.04.2019Communication of intention to grant the patent
16.07.2019Fee for grant paid
16.07.2019Fee for publishing/printing paid
16.07.2019Receipt of the translation of the claim(s)
Opposition(s)Opponent(s)01  28.05.2020    ADMISSIBLE
Grund, Dr., Martin
Nikolaistr. 15
80802 Munich / DE
Opponent's representative
Grund, Martin
Grund Intellectual Property Group
Patentanwälte und Solicitor PartG mbB
Steinsdorfstraße 2
80538 München / DE
 [N/P]
Former [2020/27]
Opponent(s)01  28.05.2020    ADMISSIBLE
Grund, Dr., Martin
Nikolaistr. 15
80802 Munich / DE
Opponent's representative
Grund, Martin
Grund Intellectual Property Group
Patentanwalt und Solicitor PartG mbB
Postfach 44 05 16
80754 München / DE
17.06.2020Invitation to proprietor to file observations on the notice of opposition
26.10.2020Reply of patent proprietor to notice(s) of opposition
17.11.2021Legal effect of rejection of opposition [2022/18]
17.11.2021Date of oral proceedings
13.12.2021Despatch of minutes of oral proceedings
13.12.2021Date of despatch of rejection of opposition
Fees paidRenewal fee
31.05.2017Renewal fee patent year 03
28.11.2018Renewal fee patent year 04
31.05.2019Renewal fee patent year 05
Penalty fee
Additional fee for renewal fee
31.05.201804   M06   Fee paid on   28.11.2018
Opt-out from the exclusive  Tooltip
competence of the Unified
Patent Court		 See the Register of the Unified Patent Court for opt-out data
Responsibility for the accuracy, completeness or quality of the data displayed under the link provided lies entirely with the Unified Patent Court.
Lapses during opposition  TooltipHU04.05.2015
AL28.08.2019
CY28.08.2019
CZ28.08.2019
EE28.08.2019
HR28.08.2019
LT28.08.2019
LV28.08.2019
MC28.08.2019
MK28.08.2019
MT28.08.2019
PL28.08.2019
RO28.08.2019
RS28.08.2019
SI28.08.2019
SK28.08.2019
SM28.08.2019
BG28.11.2019
GR29.11.2019
IS28.12.2019
PT30.12.2019
LU04.05.2020
[2022/32]
Former [2022/28]HU04.05.2015
AL28.08.2019
CY28.08.2019
CZ28.08.2019
EE28.08.2019
HR28.08.2019
LT28.08.2019
LV28.08.2019
MC28.08.2019
MT28.08.2019
PL28.08.2019
RO28.08.2019
RS28.08.2019
SI28.08.2019
SK28.08.2019
SM28.08.2019
BG28.11.2019
GR29.11.2019
IS28.12.2019
PT30.12.2019
LU04.05.2020
Former [2021/15]AL28.08.2019
CZ28.08.2019
EE28.08.2019
HR28.08.2019
LT28.08.2019
LV28.08.2019
MC28.08.2019
PL28.08.2019
RO28.08.2019
RS28.08.2019
SI28.08.2019
SK28.08.2019
SM28.08.2019
BG28.11.2019
GR29.11.2019
IS28.12.2019
PT30.12.2019
LU04.05.2020
Former [2021/12]AL28.08.2019
CZ28.08.2019
EE28.08.2019
HR28.08.2019
LT28.08.2019
LV28.08.2019
MC28.08.2019
PL28.08.2019
RO28.08.2019
RS28.08.2019
SI28.08.2019
SK28.08.2019
SM28.08.2019
BG28.11.2019
GR29.11.2019
IS28.12.2019
PT30.12.2019
Former [2020/37]AL28.08.2019
CZ28.08.2019
EE28.08.2019
HR28.08.2019
LT28.08.2019
LV28.08.2019
PL28.08.2019
RO28.08.2019
RS28.08.2019
SI28.08.2019
SK28.08.2019
SM28.08.2019
BG28.11.2019
GR29.11.2019
IS28.12.2019
PT30.12.2019
Former [2020/36]AL28.08.2019
CZ28.08.2019
EE28.08.2019
HR28.08.2019
LT28.08.2019
LV28.08.2019
PL28.08.2019
RO28.08.2019
RS28.08.2019
SK28.08.2019
SM28.08.2019
BG28.11.2019
GR29.11.2019
IS28.12.2019
PT30.12.2019
Former [2020/27]AL28.08.2019
CZ28.08.2019
EE28.08.2019
HR28.08.2019
LT28.08.2019
LV28.08.2019
PL28.08.2019
RO28.08.2019
RS28.08.2019
SK28.08.2019
SM28.08.2019
BG28.11.2019
GR29.11.2019
PT30.12.2019
IS24.02.2020
Former [2020/25]AL28.08.2019
CZ28.08.2019
EE28.08.2019
HR28.08.2019
LT28.08.2019
LV28.08.2019
PL28.08.2019
RO28.08.2019
RS28.08.2019
SK28.08.2019
BG28.11.2019
GR29.11.2019
PT30.12.2019
IS24.02.2020
Former [2020/24]AL28.08.2019
EE28.08.2019
HR28.08.2019
LT28.08.2019
LV28.08.2019
PL28.08.2019
RO28.08.2019
RS28.08.2019
BG28.11.2019
GR29.11.2019
PT30.12.2019
IS24.02.2020
Former [2020/23]AL28.08.2019
EE28.08.2019
HR28.08.2019
LT28.08.2019
LV28.08.2019
PL28.08.2019
RO28.08.2019
RS28.08.2019
BG28.11.2019
GR29.11.2019
IS28.12.2019
PT30.12.2019
Former [2020/22]AL28.08.2019
EE28.08.2019
HR28.08.2019
LT28.08.2019
LV28.08.2019
RS28.08.2019
BG28.11.2019
GR29.11.2019
IS28.12.2019
PT30.12.2019
Former [2020/15]AL28.08.2019
HR28.08.2019
LT28.08.2019
LV28.08.2019
RS28.08.2019
BG28.11.2019
GR29.11.2019
IS28.12.2019
PT30.12.2019
Former [2020/12]HR28.08.2019
LT28.08.2019
LV28.08.2019
RS28.08.2019
BG28.11.2019
GR29.11.2019
IS28.12.2019
PT30.12.2019
Former [2020/11]HR28.08.2019
LT28.08.2019
LV28.08.2019
RS28.08.2019
BG28.11.2019
GR29.11.2019
PT30.12.2019
Former [2020/10]LT28.08.2019
BG28.11.2019
PT30.12.2019
Former [2020/08]LT28.08.2019
Cited inOppositionCN103724410
 WO2011146121
 WO2013074999
   NEVILLE E SANJANA, CONG LE, ZHOU YANG, CUNNIFF MARGARET M, FENG GUOPING, ZHANG FENG: "A transcription activator-like effector toolbox for genome engineering", NATURE PROTOCOLS, vol. 7, no. 1, 5 January 2012 (2012-01-05), GB, pages 171 - 192, XP055548736, ISSN: 1754-2189, DOI: 10.1038/nprot.2011.431 * (cited as D5 in examination proceedings) *

DOI:   http://dx.doi.org/10.1038/nprot.2011.431
   MILLER JEFFREY C. ET AL., NAT. BIOTECH., vol. 29, no. 2, 2011, pages 143 - 148, XP055568321 * , together with online methods section and supplementary information. *

DOI:   http://dx.doi.org/10.1038/nbt.1755
   LE CONG, ZHOU RUHONG, KUO YU-CHI, CUNNIFF MARGARET, ZHANG FENG: "Comprehensive interrogation of natural TALE DNA-binding modules and transcriptional repressor domains", HHS PUBLIC ACCESS AUTHOR MANUSCRIPT, vol. 3, no. 1, 1 January 2012 (2012-01-01), pages 1 - 13, XP055598267, DOI: 10.1038/ncomms1962

DOI:   http://dx.doi.org/10.1038/ncomms1962
   STREUBEL J, BLCHER C, LANDGRAF A, BOCH J.: "TAL effector RVD specificities and efficiencies.", NATURE BIOTECHNOLOGY, vol. 30, no. 7, 1 July 2012 (2012-07-01), pages 593 - 595, XP002700146, ISSN: 1546-1696, DOI: 10.1038/nbt.2304

DOI:   http://dx.doi.org/10.1038/nbt.2304
   C. MUSSOLINO, MORBITZER R., LUTGE F., DANNEMANN N., LAHAYE T., CATHOMEN T.: "A novel TALE nuclease scaffold enables high genome editing activity in combination with low toxicity", NUCLEIC ACIDS RESEARCH, vol. 39, no. 21, 1 November 2011 (2011-11-01), pages 9283 - 9293, XP055021128, ISSN: 03051048, DOI: 10.1093/nar/gkr597 * (D1 in the examination proceedings; together with supplemental data) *

DOI:   http://dx.doi.org/10.1093/nar/gkr597
   DOYLE ET AL.: "TAL Effector-Nucleotide Targeter (TALE-NT) 2.0: tools for TAL effector design and target prediction", NUCLEIC ACID RESEARCH, vol. 40, no. W1, 2012, pages W117 - W122, XP055073827

DOI:   http://dx.doi.org/10.1093/nar/gks608
   YUANXI FENG; SILIANG ZHANG; XIN HUANG: "A robust TALENs system for highly efficient mammalian genome editing", SCIENTIFIC REPORTS, vol. 4, no. 3632, 2014, pages 1 - 7, XP055196360

DOI:   http://dx.doi.org/10.1038/srep03632
The EPO accepts no responsibility for the accuracy of data originating from other authorities; in particular, it does not guarantee that it is complete, up to date or fit for specific purposes.